Entrada Therapeutics, Inc.
TRDA
$7.46
$0.010.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 2.63% | -32.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.63% | -32.64% | |||
| Cost of Revenue | 7.00% | 2.47% | |||
| Gross Profit | -7.12% | -3.94% | |||
| SG&A Expenses | 3.63% | 8.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.21% | 3.78% | |||
| Operating Income | -6.29% | -4.95% | |||
| Income Before Tax | -7.68% | -1.55% | |||
| Income Tax Expenses | -7.89% | -58.70% | |||
| Earnings from Continuing Operations | -7.67% | -1.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.67% | -1.41% | |||
| EBIT | -6.29% | -4.95% | |||
| EBITDA | -6.32% | -5.27% | |||
| EPS Basic | -6.69% | -0.84% | |||
| Normalized Basic EPS | -6.70% | -6.16% | |||
| EPS Diluted | -6.69% | -0.84% | |||
| Normalized Diluted EPS | -6.70% | -6.16% | |||
| Average Basic Shares Outstanding | 0.92% | 0.56% | |||
| Average Diluted Shares Outstanding | 0.92% | 0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||